Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795270 | 1.00 | S1PR5 (0.62) | S1PR5POLBSIGMAR1MCHR1CCR3 | |
| SCHEMBL7304448 | 0.92 | MCHR1 (0.65) | SIGMAR1MCHR1CCR3ACHEKMT2A | |
| SCHEMBL250506 | 0.84 | S1PR5 (0.77) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| SCHEMBL9037650 | 0.84 | S1PR5 (0.77) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| SCHEMBL16301219 | 0.84 | S1PR5 (0.77) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL892739 | 0.83 | S1PR5 (0.75) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL892740 | 0.83 | S1PR5 (0.75) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL893221 | 0.83 | S1PR5 (0.75) | S1PR5KMT2AS1PR4S1PR1S1PR3 | |
| SCHEMBL7417801 | 0.83 | MCHR1 (0.68) | SIGMAR1MCHR1CCR3ACHEKMT2A | |
| SCHEMBL4662752 | 0.81 | S1PR5 (0.62) | S1PR5S1PR4S1PR1S1PR3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | S1PR5 3915/4885POLB 419/4885SIGMAR1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.